^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    BRCA1 mutation

    i
    Other names: BRCA1, BRCC1, PPP1R53, RNF53, Breast cancer 1, early onset
    Entrez ID:
    672
    Related biomarkers:
    Expression
    Mutation
    CNA
    Fusion
    Others
    Related tests:
    9ms
    Thanks to @AlisonsAllies for supporting our work on understanding metabolic signatures for #breastcancer risk in #BRCA1 mutation carriers. @DrLaurenNye https://t.co/BRXbq9g2Lc (@shanestecklein)
    BRCA1 (Breast cancer 1, early onset)
    |
    BRCA1 mutation
    10ms
    New #ETCTN #solidtumor #clinicaltrial: (10551) “A Phase I/Ib Study of Anti-CD47 Hu5F9-G4 (Magrolimab) in Combination With Olaparib in Patients With BRCA1/2-Mutant Tumors”, led by @HaiderMahdiMD of @UPMCHillmanCC. Learn more about this #CancerResearch: https://t.co/kzCT7a7Zuf (@NCICTEP_ClinRes)
    Clinical • Combination therapy
    |
    BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset)
    |
    BRCA2 mutation • BRCA1 mutation
    |
    Lynparza (olaparib) • magrolimab (GS-4721)
    10ms
    #17ICML P Ghione: Career women of BRCA1/2 mutations are at 12-times higher of developing a breast-implanted associated anaplastic large cell lymphoma #lymsm (@DrRaulCordoba)
    BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset)
    |
    BRCA2 mutation • BRCA1 mutation
    11ms
    A phase II basket trial shows an antitumor activity for olaparib in metastatic castrate-resistant prostate cancer and BRCA1/2 mutations https://t.co/yCdmhZTCJT #fondazionebonadonna #CancerResearch #oncology @BianchiniGP @CarmenCriscit @mauricallari (@FondazioneBona1)
    Pan tumor • Metastases
    |
    BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset)
    |
    BRCA2 mutation • BRCA1 mutation
    |
    Lynparza (olaparib)
    11ms
    New study shows Talazoparib may be effective in treating advanced solid tumors with BRCA1/2 mutations. -Tala was shown to have a 57% disease control rate in patients with BRCA1/2 mutations. @rschilsky @ASCO #ASCO23 @OncoAlert https://t.co/vefBI9AbCF https://t.co/TgVygc7ylR (@DrYukselUrun)
    Clinical • Metastases
    |
    BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset)
    |
    BRCA2 mutation • BRCA1 mutation
    |
    Talzenna (talazoparib)
    11ms
    TAPUR Study: Talazoparib May Have Antitumor Activity in Range of Solid Tumors With BRCA1/2 Mutations https://t.co/Z7Z46qAWQ1 @asco #ASCO23 @GlopesMd (@GlopesMd)
    BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset)
    |
    BRCA2 mutation • BRCA1 mutation
    |
    Talzenna (talazoparib)
    11ms
    New findings from our clinical trial, #TAPUR, at #ASCO23 highlight promising data on nivolumab + ipilimumab in patients with ovarian cancer with a BRCA1/2 mutation: https://t.co/0dN6Sr48xe @rschilsky #ASCODailyNews #gyncsm (@ASCO)
    Clinical
    |
    BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset)
    |
    BRCA2 mutation • BRCA1 mutation
    |
    Opdivo (nivolumab) • Yervoy (ipilimumab)
    12ms
    Dr. Filipa Lynce (@FilipaLynce) presented her phase Ib study of sapacitabine and olaparib in patients with BRCA1/2-mutated (BRCA1/2m) metastatic breast cancer (#MBC) at the @df_hcc Breast and Gynecologic Cancer Symposium. https://t.co/oLcCGG7UPd (@DFCI_BreastOnc)
    Clinical • Metastases
    |
    BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset)
    |
    BRCA2 mutation • BRCA1 mutation
    |
    Lynparza (olaparib) • sapacitabine (CYC682)
    12ms
    Fantastic talk by @FilipaLynce on new data from a phase Ib study of sapacitabine and olaparib in patients with BRCA1/2-mutated metastatic breast cancer. Important insights into mechanisms of response. @DFCI_BreastOnc @DanaFarberBRCA (@JennGuerriero)
    Clinical • P1 data • Metastases
    |
    BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset)
    |
    BRCA2 mutation • BRCA1 mutation
    |
    Lynparza (olaparib) • sapacitabine (CYC682)
    12ms
    @PTarantinoMD are you seeing carboplatin success in late-stage TNBC gated by BRCA1/2 mutation status? (@jeff7091)
    BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset)
    |
    BRCA2 mutation • BRCA1 mutation
    |
    carboplatin
    12ms
    I am sorry for the loss of your dad.Thank you for sharing this loving photo & for all you do for your patients & to educate on the importance of family history. We learned of BRCA1 mutation in ours 20 yrs ago when my sis was d/x w/ovarian cancer & grandmother before her in 1956. (@bettylo52207153)
    Clinical
    |
    BRCA1 (Breast cancer 1, early onset)
    |
    BRCA1 mutation
    1year
    H.Pylori infection significantly increases the risk of gastric cancer in persons with inherited mutations in BRCA2, BRCA1 , ATM, and PALB2 compared to non-carriers. The good news is that eradicating H.Pylori is relatively easy and may help mitigate risk. https://t.co/weMai50Ja1 (@Ecastromarcos)
    BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • PALB2 (Partner and localizer of BRCA2)
    |
    BRCA1 mutation • ATM mutation • PALB2 mutation
    1year
    Congratulations Andy Futreal @MDAndersonNews for your induction as a Fellow of the @AACR Academy for seminal contributions to genomics. My patients benefit each day from your groundbreaking work discovering BRAF mutations in #melanoma and cloning BRCA1 and BRCA2. (@mcquadeMDLAc)
    Clinical
    |
    BRAF (B-raf proto-oncogene) • BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset)
    |
    BRCA1 mutation • BRAF mutation
    1year
    📰 Rucaparib improves rPFS compared with docetaxel or ARPI in patients with BRCA1/2 mutated mCRPC previously treated with ARPI. Read the UROONCO PCa article of the Month with expert commentary 👇 https://t.co/PfDY4Icebh #prostatecancer #oncology @AlanBryce9 @DavidMorrismd (@EAU_Uroonco)
    Clinical
    |
    BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset)
    |
    BRCA2 mutation • BRCA1 mutation
    |
    docetaxel • Rubraca (rucaparib)
    1year
    After neoadjuvant talazoparib results in BRCAm BC (Litton J.K. 2017), neoadjuvant olaparib in #ovariancancer (with mutation in BRCA1/2, RAD51C/D, or PALB2) by @ShannonWestin shows outstanding surgical outcomes after only 2 cycles of olaparib, even in Stage IV pts #SGOMTG #SGO2023 (@AllegraRollo)
    Clinical • Metastases
    |
    BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • PALB2 (Partner and localizer of BRCA2) • RAD51C (RAD51 paralog C) • RAD51D (RAD51 paralog D)
    |
    BRCA2 mutation • BRCA1 mutation • PALB2 mutation • RAD51C mutation • RAD51 mutation
    |
    Lynparza (olaparib) • Talzenna (talazoparib)
    1year
    Today is TNBC- #TripleNegativeBreastCancerDay. TNBC is more common in women younger than age 40, who are Black, or who have a BRCA1 mutation. TNBC can be more aggressive but patients are doing better today than in the past- #earlydetection and https://t.co/WrwLrKFuZ8… https://t.co/grYKBz0el0 (@Latinamd)
    Clinical
    |
    BRCA1 (Breast cancer 1, early onset)
    |
    BRCA1 mutation
    1year
    CHMP recommends naraparib/abi for 1st line CRPC with BRCA1/2 mutations only, based on MAGNITUDE, but this had a wider HRR biomarker panel (ATM, BRIP1, CDK12, CHEK2, FANCA, HDAC2, PALB2). Are these just passengers?⬆️ momentum for BRCA for PARPi in CRPC https://t.co/ZjbyXDxo27 (@tompowles1)
    BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • PALB2 (Partner and localizer of BRCA2) • CDK12 (Cyclin dependent kinase 12) • BRCA (Breast cancer early onset) • CHEK2 (Checkpoint kinase 2) • FANCA (FA Complementation Group A) • BRIP1 (BRCA1 Interacting Protein C-terminal Helicase 1) • HDAC2 (Histone deacetylase 2)
    |
    BRCA2 mutation • BRCA1 mutation • CDK12 mutation • CHEK2 mutation • BRIP1 mutation • FANCA mutation
    1year
    Interesting study from @BrownLab_WCM (with @CantleyLab) in @ScienceTM: Obesity promotes breast epithelium DNA damage in women carrying a germline mutation in BRCA1 or BRCA2 https://t.co/OswkUO4xFd While focused on #BreastCancer risk, intriguing implications for #PancreaticCancer (@Aiims1742)
    BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset)
    |
    BRCA2 mutation • BRCA1 mutation
    1year
    ASCO GU 2023 Day 1 Take Home: PARPi's! 2) TRITON-3: rucaparib (PARPi) improved rPFS vs physicians choice (doce/abi/enza) in mCRPC with BRCA1/2 mutations after ARPi (abi/enza) progression @AlanBryce9 #ASCOGU23 #ascogu2023 #ASCOGU (@KrisWentzelMD)
    BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset)
    |
    BRCA2 mutation • BRCA1 mutation
    |
    Rubraca (rucaparib) • abiraterone acetate
    1year
    In high-grade #ovariancancer The magnitude of benefit from olaparib may be related to the location of the mutation in BRCA1/2 🧬🧬 @Annals_Oncology @myESMO @OncoAlert @VJOncology @ESGO_society @acog @ASCO @agz_eriksson @IGCSociety @SGO_org @VukovicPetra https://t.co/onKN4CSoCy (@DrYukselUrun)
    BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset)
    |
    BRCA2 mutation • BRCA1 mutation
    |
    Lynparza (olaparib)
    over1year
    Prostate cancer risk, screening and management in patients with germline BRCA1/2 mutations | Nature Reviews Urology https://t.co/CPoeFS0LMa (@drdeniztural)
    Clinical
    |
    BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset)
    |
    BRCA2 mutation • BRCA1 mutation
    over1year
    There is strong evidence that short-term HRT use does not increase the risk of breast cancer among women with a BRCA1 mutation. Few data are available on BRCA2 mutation carriers. https://t.co/vR9RUSBDfA (@KefahMokbel)
    BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset)
    |
    BRCA2 mutation • BRCA1 mutation
    over1year
    Prostate cancer risk, screening, and management in patients with germline BRCA1/2 mutations @NatRevUrol @DrShariat @gpalapa2 @Albert0Briganti @wandering_gu @amerseburger @Tilki_De @gorejohn @mleapman @GPloussard @GGandaglia @BenjaminPradere @FQuhal https://t.co/LNt63xaGps (@dr_rajwa)
    Clinical
    |
    BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • HSP90AA1 (Heat Shock Protein 90 Alpha Family Class A Member 1Heat Shock Protein 90 Alpha Family Class A Member 1)
    |
    BRCA2 mutation • BRCA1 mutation
    over1year
    Analysis of matched primary and recurrent BRCA1/2 mutation-associated tumors identifies recurrence-specific drivers https://t.co/23tgIIZtF3 #bcsm (@aftimosp)
    BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset)
    |
    BRCA2 mutation • BRCA1 mutation
    over1year
    Last NGS analysis of 2022 had a surprise & I found 2 new #FounderMutation in #BRCA1 in a #Manipuri community & in BRCA2 gene in a #Maharashtrian community Happy as it opens avenues for cost effective & rapid genetic testing for #Breast & #Ovarian cancer cases in these communities (@RajivSarin5)
    Clinical • HEOR • Next-generation sequencing • Cost effectiveness
    |
    BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset)
    |
    BRCA1 mutation
    over1year
    I’d add Ashkenazi Jewish ancestry to characteristics that may make it more likely that a woman with breast cancer has a BRCA1/2 mutation. (@HHampel1)
    BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset)
    |
    BRCA2 mutation • BRCA1 mutation
    over1year
    Challenging なstudyかなと BRCA1の女性に対してRRSのみで卵巣癌を予防できるかを検証 FORCE | A Study to Compare Two Surgical Procedures in Women with BRCA1 Mutations to Assess Reduced Risk of Ovarian Cancer (SOROCk) https://t.co/u3Mgei3Dkz (@0109Ayumi)
    BRCA1 (Breast cancer 1, early onset)
    |
    BRCA1 mutation
    over1year
    .@SidYadavMD presents pop-based study of rates of contralateral breast ca in genetic mutation carriers - 10yr CBC absolute risk was 23% in BRCA1 & 17% in BRCA2. ⬆️ also for CHEK2. Unknown endocrine tx use. Important data when discussing contralateral RRM w/ pts #SABCS22 (@puneetsinghmd)
    Clinical • Absolute risk
    |
    BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • CHEK2 (Checkpoint kinase 2)
    |
    BRCA1 mutation • CHEK2 mutation
    over1year
    Association of location of BRCA1 and BRCA2 mutations with benefit from olaparib and bevacizumab maintenance in high-grade ovarian cancer: Phase III PAOLA-1/ENGOT-ov25 trial subgroup exploratory analysis - ScienceDirect https://t.co/JyiMoQ8qGH (@0109Ayumi)
    Clinical
    |
    BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset)
    |
    BRCA2 mutation • BRCA1 mutation • BRCA1 mutation + BRCA2 mutation
    |
    Avastin (bevacizumab) • Lynparza (olaparib)
    over1year
    You may be at increased risk for a BRCA1 or BRCA2 mutation if your family history includes— •Several relatives with breast cancer. •Any relatives with ovarian cancer. •Relatives who got breast cancer before age 50. •A relative with cancer in both breasts.#PancChat (@drallysonocean)
    BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset)
    |
    BRCA2 mutation • BRCA1 mutation
    over1year
    This study identifies breast cancer patients with inherited PALB2 mutations as uniquely sensitive to Parp inhibitors. Our trial design excluded BRCA1/2 mutations. (@joshuagruber)
    Clinical
    |
    BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • PALB2 (Partner and localizer of BRCA2)
    |
    BRCA2 mutation • BRCA1 mutation • PALB2 mutation
    over1year
    BRCA reversion mutations are a significant mechanism of acquired resistance to Rucaparib in patients with BRCA1 or 2 mutated met castration-resistant #prostate #Cancer @EUplatinum @OncoAlert @AkashPatnaik7 @cdanicas @Uroweb @APCCC_Lugano @scserendipity1 https://t.co/Mgn77tRHIs (@DrYukselUrun)
    Clinical
    |
    BRCA1 (Breast cancer 1, early onset) • BRCA (Breast cancer early onset) • CAST (Calpastatin)
    |
    BRCA1 mutation • MET mutation • BRCA mutation
    |
    Rubraca (rucaparib)
    over1year
    Very exciting news to be able to detect by ctDNA a BRCA1 mutation in cholangiocarcinoma, which definitely will open possibilities for more therapy options such as targeted therapies and clinical trials @pashtoonkasi (@Perthera)
    Clinical • Circulating tumor DNA
    |
    BRCA1 (Breast cancer 1, early onset)
    |
    BRCA1 mutation
    over1year
    👇Check out our analysis of the differential genomic landscape of BRCA1 vs BRCA2 mutated advanced prostate cancer using cfDNA led by @umangtalking @PCF_Science @PCFnews @huntsmancancer @Huntsman_GU (@nsayeghmd)
    BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset)
    |
    BRCA2 mutation • BRCA1 mutation
    over1year
    Just in @FrontOncology from our faculty & others: Differential genomic landscape of BRCA1 vs BRCA2 mutated advanced #prostatecancer in 7,707 patients with cfDNA genomic profiling👇@umangtalking @neerajaiims @urotoday @OncoAlert @GuardantHealth Link👉 https://t.co/IzWaSt7Sko (@Huntsman_GU)
    Clinical
    |
    BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset)
    |
    BRCA2 mutation • BRCA1 mutation
    over1year
    Background: Up to 25% of people with ovarian cancer are related to a hereditary cancer-associated mutation. The most common of these involve BRCA1 or BRCA2. #BrownJC 2/9 #gyncsm (@drdonsdizon)
    BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset)
    |
    BRCA1 mutation
    over1year
    Surgery to prevent ovarian cancer is offered to people with mutations in BRCA1 or BRCA2, typically between ages of 35-45. #BrownJC 3/9 #gyncsm (@drdonsdizon)
    BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset)
    |
    BRCA2 mutation • BRCA1 mutation
    over1year
    In case you missed this last week. Our own @VKaklamani on the Use of Adjuvant Olaparib in Germline BRCA1/2-Mutant Breast Cancer https://t.co/PYL4Pv4Yhv via @onclive (@SABCSSanAntonio)
    Clinical
    |
    BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset)
    |
    BRCA2 mutation • BRCA1 mutation
    |
    Lynparza (olaparib)
    over1year
    MyChoice CDx examines ovarian cancer tumors using two individual methods (BRCA1/2 mutation and genomic instability) to determine a patients HRD staus. ()
    Clinical
    |
    BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset)
    |
    BRCA2 mutation • BRCA1 mutation
    |
    Myriad myChoice® CDx
    over1year
    Significant vitamin d deficiency at dx and prior five years super common in my clients w/TNBC sans BRCA1 mutation. VDR needed for important P53 functions which trigger eventual BRCA1 expression. Sure wish we could know D levels in the controls that respond to PARPi. Low? (@nursekristinrn)
    BRCA1 (Breast cancer 1, early onset)
    |
    TP53 mutation • BRCA1 mutation • BRCA1 expression
    over1year
    #TumorBoardTuesday I am always quick to point out that PARP inhibitors have been shown to be helpful in some #PancreaticCancer patients with SOMATIC only BRCA1/2 mutations Can this be true in #breastcancer too? How about #ovariancancer ? (@MPishvaian)
    Clinical
    |
    BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset)
    |
    BRCA2 mutation • BRCA1 mutation
    almost2years
    .@EAntonarakis et al report on monoallelic BRCA1/2 mutations that occur in the context of mismatch repair deficiency or microsatellite instability, are not primary driver events, and may not sensitize to PARP inhibitor treatments: https://t.co/ypxJjGltGg #pcsm #bcsm #pancsm (@JCOPO_ASCO)
    Mismatch repair
    |
    BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • MSI (Microsatellite instability)
    |
    BRCA2 mutation • BRCA1 mutation